Back to announcement
20260409_PYFA_Laporan Hasil Pemeringkatan_32069565_lamp1.pdf
Other Text extracted PYFASource file signed link, expires in 15 minutes
Extracted text 2
Page 1
Press Release
KREDIT RATING INDONESIA March 31, 2026
PT Pyridam Farma Tbk
Company Rating irA-/Stable "Debt Securities with irA rating has a high
level of certainty to honor its financial
Rated Issues obligations, but it can be affected by adverse
Obligasi Berkelanjutan I Pyridam Farma changes in business and economic
Tahap I Tahun 2022 irA- conditions, relative to debt securities with a
Obligasi Berkelanjutan II Pyridam Farma irA-
higher rating.”
The minus sign (-) indicates that the rating is
Rating Period still higher than the rating category below,
March 31, 2026 – April 1, 2027 although it is closer to the lower rating than
it is to the higher rating category.
Rating History
April 2025 irA-/Stable
October 2024 irBBB+/Stable
October 2023 irBBB+/Stable
October 2022 irBBB+/Stable
November 2021 irBBB+/Stable
October 2021 irBBB+/Stable
October 2020 irBBB/Stable
Kredit Rating Indonesia affirms “irA-” rating for PT Pyridam Farma Tbk. The Outlook for
the Company Rating is “Stable”. KRI also affirms “irA-” rating for Obligasi Berkelanjutan
I Pyridam Farma Tahap I Tahun 2022 and Obligasi Berkelanjutan II Pyridam Farma
Kredit Rating Indonesia (“KRI”) affirms “irA-” rating for PT Pyridam Farma Tbk (“PYFA” or “the
Company”). Outlook for the Company Rating is “Stable”. At the same time, KRI has also affirmed “irA-”
rating to Obligasi Berkelanjutan I Pyridam Farma Tahap I Tahun 2022 amounting to IDR 1.2 trillion and
Obligasi Berkelanjutan II Pyridam Farma amounting to IDR 1.5 trillion. The ratings still reflect our view
related to the Company’s diverse product portfolio and solid business performance. However, the
ratings are still constrained by the Company’s financial profile.
PYFA has significantly expanded its footprint through the acquisition of Probiotec Pte Ltd (“Probiotec”),
a publicly listed Australian pharmaceutical and packaging firm. This move diversifies PYFA’s revenue
streams across generics, injectable, prescription medicines, medical equipment, and packaging
services, enhancing long-term financial stability. Consequently, 9M2025 revenue reached
IDR 2.06 trillion—already surpassing the FY24 total of IDR 1.92 trillion—driven largely by Probiotec’s
50% contribution. Furthermore, the acquisition is expected to elevate PYFA’s operational quality by
integrating Probiotec’s world-class healthcare standards.
However, the Company’s ratings are still constrained by the Company’s coverage ratio as the Interest
Coverage Ratio remained weak (0.34x in 9M2025 versus 0.3x in FY24), and Funds From Operations
(FFO) Debt Ratio of (2.7%) in 9M2025 (versus 6.5% in FY24).
Established in 1976, PYFA is a national pharmaceutical company with the Company’s shareholder
ownership composition as of September 30, 2025 were Rejuve Global Investment Pte. Ltd. (60.45%),
PT Asuransi Jiwa Starinvestama (5.10%), and the public (34.45%).
PT Pyridam Farma Tbk Page 1
Page 2
Press Release
KREDIT RATING INDONESIA March 31, 2026
PYFA Financial Result Highlights (Consolidated)
Sep 2025 Dec 2024 Dec 2023 Dec 2022
As of/For the years ended
(Unaudited) (Audited) (Audited) (Audited)
Total Assets (IDR, billion) 4,156.5 3,222.7 1,502.1 1,509.4
Total Adjusted Debt (IDR, billion) 5,060.6 3,867.0 987.0 910.0
Total Adjusted Equity (IDR, billion) (2,030.1) (1,548.9) 337.7 431.0
Total Sales (IDR, billion) 2,060.2 1,920.8 702.1 715.4
EBIT (IDR, billion) (150.7) (16.3) (7.8) (35.6)
Net Income After MI (IDR, billion) (365.8) (330.3) (85.2) 275.5
EBIT Margin (%) (7.3) (9.9) (1.1) (5.0)
Return on Permanent Capital (%) 0.0 0.0 (0.6) (3.7)
Adjusted Debt/Adjusted Equity (x) N.M N.M 2.9 2.1
EBITDA/Total Adjusted Debt (x) 0.0 0.0 0.0 0.1
EBITDA/IFCCI (x) 0.3 0.3 0.5 0.5
FFO/Total Adjusted Debt (%) (2.7) (6.5) (3.6) 30.3
USD Exchange Rate (IDR/USD) 16,680 16,162 15,416 15,731
Analysts Cut Nabila Saraziva (cut.nabila@kreditratingindonesia.com)
Samuel Aditya Pangestu Sitorus (samuel.sitorus@kreditratingindonesia.com)
DISCLAIMER
PT Kredit Rating Indonesia (KRI) does not represent or warrant or guarantee the accuracy, completeness, timeliness or
availability of the contents of this report or publication. KRI does not perform an audit and does not undertake due diligence or
independent verification of any information used as the basis of and presented in this report or publication. Although the
information upon which KRI rating report are based, and any other contents provide in this rating report is obtained by KRI from
sources which KRI believers to be reliable.
KRI will be held harmless against any responsibility arising from its use, its partial use, or its lack of use, in combination with other
products or used solely, nor can it be held responsible for the result of its use or lack of its use in any investment or other kind of
financial decision making on which this report or publication is based. The issuance of a solicited or unsolicited rating report does
not supply financial, legal, tax or investment consultancy. The rating report is not an opinion as to the value of securities, therefore
KRI is not responsible for any credit, loan or investment decision, damages or other losses resulting from the reliance upon or
use of this report.
In no event shall KRI be held liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential
damages, costs, expenses, legal fees, or losses including but not limited to lost profits and opportunity costs in connection with
any use of the contents of this rating report or publication.
Credit analyses, including ratings, and statements in this report or publication are statements of opinion as of the date they are
expressed and not statements of fact or recommendations to purchase, hold or sell any securities or to make any investment
decision. Therefore, this report may not reflect any event or circumstances which occur after the date of this report.
KRI also assumes no obligation to update the content following publication in any form. KRI does not act as fiduciary or an
investment advisor. KRI keeps the activities of its analytical units separate from its business units to preserve independence and
objectivity of its analytical process and products. As a result, certain units of KRI may have information that is not available to
other units. KRI has established policies and procedures to maintain the confidentiality of certain non-public information received
in connection with each analytical process. KRI may receive compensation for its ratings and other analytical work, normally from
issuers of securities. KRI reserves the right to disseminate its opinions and analyses. KRI’s public ratings and analyses are made
available on its website, http://www.kreditratingindonesia.com (free of charge) and through other subscription based services,
and may be distributed through other means, including via KRI publications and third party redistributors. Information in KRI’s
website and its use fall under the restrictions and disclaimer stated above. No part of KRI’s website, the content of this report,
may be reproduced or transmitted by any means, electronic or non-electronic whether in full or in part, will be subjected to written
approval from KRI.
PT Pyridam Farma Tbk Page 2
Names mentioned 4 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Asuransi Jiwa Starinvestama
p.1
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.